Revenue Growth - FY 2024 revenue increased 32.9% year over year to 28.34million,upfrom21.33 million in FY 2023[5] - Revenue from direct patient services segment surged 253.4% year over year to 12.56million,comparedto3.55 million in FY 2023[5] - Q4 2024 revenue increased 59.2% to 9.07millioncomparedto5.70 million in Q4 2023, driven by expanded radiation therapy services[11] - Q4 2024 revenue from direct patient services segment was 4.75million,a420.22.19 million, or 0.34perdilutedshare,comparedto610,000, or 0.10perdilutedshareinFY2023[9]−TheoverallnetincomeforthetwelvemonthsendedDecember31,2024,was2,186,000, compared to 610,000in2023,representinganincreaseofapproximately258.78.89 million from 8.19millioninFY2023[10]−AdjustedEBITDAforthetwelvemonthsendedDecember31,2024,was8,885,000, up from 8,189,000in2023,reflectingayear−over−yearincreaseofapproximately8.511.28 million as of December 31, 2024, down from 13.81millionayearearlier[16]−Shareholders′equityincreasedto25.18 million or 3.92peroutstandingshareatDecember31,2024,comparedto22.62 million or 3.59pershareatDecember31,2023[16]ExpensesandLosses−Interestexpenseincreasedto1,499,000 for the twelve months ended December 31, 2024, compared to 1,112,000in2023,representingariseofabout34.81,673,000, an increase from 1,291,000inthesameperiodof2023,showingagrowthofapproximately29.62,896,000, compared to 362,000inthesameperiodof2023,indicatingasubstantialincrease[28]TaxandInterestIncome−IncometaxbenefitforthethreemonthsendedDecember31,2024,was(71,000), a decrease from 338,000in2023,reflectingachangeintaxposition[28]−InterestincomeforthetwelvemonthsendedDecember31,2024,was(342,000), down from (458,000)in2023,indicatingadecreaseofapproximately25.3373,000, slightly down from 389,000in2023,showingadecreaseofabout4.1(148,000) for the three months ended December 31, 2024, compared to no gain in the same period of 2023[28]